Puration confirmed the developing joint venture agreement with Kali, Inc. and Nouveau Life Pharmaceuticals, Inc. to develop cannabis pharmaceutical products. Puration further confirms plans to host representatives from Kali and Nouvea in Dallas next week to finalize JV details.
“Puration is already in the wellness market and think our experience with the NCM Biotech Cannabis extraction patent will be valuable to the JV,” said Brian Shibley CEO of Puration. “I am pleased to be adding another dimension to the valuation of Puration for shareholders by tangentially entering the pharmaceuticals sector through a partnership while maintaining our internal focus on cannabis infused beverages. I’m excited to soon announce details on the new beverage we are adding through acquisition. That announcement will be coming by Friday, if not before, in a joint release from PURA and USMJ. To be clear, the JV will be excluded from developing any beverages. I’m not sure making a beverage would come up in a pharmaceutical endeavor, by Puration’s participation requires the JV partners agree that no beverage will be produced by the JV. Puration is exclusively maintaining the cannabis beverage opportunity.”
Kali, Inc has schedule an online presentation scheduled Friday, November 2nd, 2018 to detail the strategy behind the recently announced JV plans.